8 results for tag: profiteering


Is Cancer Research Money Well Spent?

When we give money to cancer research charities like Cancer Research UK we expect that money to be used efficiently but less than 2% is likely to be spent on researching new drugs that can be given to NHS cancer patients as a routine treatment.

Time To Rethink How We Pay for Medical Research

Our medical R&D system is undermining our health – reform could boost our economy and our wellbeing. It’s time we implemented a new, more efficient, collaboratively driven, open innovation model with patient needs at its heart.

NHS Can’t Afford Half New Cancer Drugs

Half of new cancer drugs are too pricey for the NHS due to profiteering by drug companies. The Government is choosing to leave patients to die early rather than exercise its legal powers to obtain the newer, more effective drugs from a cheaper alternative source.

Cancer Drug Costs Could Be Halved

The cost of developing new cancer drugs could be halved at least if we cooperated across the world to publicly fund R&D, using cheaper finance, eliminating wasteful duplication and developing drugs for public benefit not for profit.

Campaign Letter to Health Secretary

With support for the Dying for a Cure campaign growing, a letter has been sent today to the Secretary of State for Health, Jeremy Hunt, setting out the issues and sharing with him a sample of comments from supporters.

Drug Firms Pass On £25bn Fines To Patients

A shocking new study has revealed pharmaceutical companies have been fined more than £25bn over the last 25 years for illegal activity aimed at boosting profits. Patients are ultimately paying the price for this through higher drug prices.

£99 Cancer Drug Being Sold for £83,000

Shocking new evidence has come to light of massive profiteering from cancer drugs - one cancer drug that costs only £99 to make is being being sold for up to £83,000, despite R&D costs being paid back over 10 years years ago.

Cancer Drugs Priced Out of Reach

News about a promising new breast cancer treatment combining Herceptin and Tyverb is dampened by the prospect that the drugs may be too expensive for the NHS.